What is already known about this topic:
Patients with respiratory disease are particularly likely to have poor adherence to medicines due to complex medication regimens and difficulty using inhaler devices.
It is unknown whether patients with asthma and COPD have different medication use behaviours.
What this article adds:
Adherence for maintenance inhaler therapies in respiratory disease is low, but higher among patients with COPD compared to patients with asthma.
Less than 20% of patients in this UK cohort with respiratory disease remained persistent with inhaled therapy at one year. Medication adherence refers to the degree to which a patient's medication-taking behaviour coincides with agreed medical advice, and largely has supplanted the term 'compliance,' which infers a clinician-directed therapy decision without patient input.
[1] Medication persistence examines whether a patient follows the recommendation of continuing treatment for a prescribed length of time. [2] According to the World Health Organization (WHO), approximately half of patients across the world are non-adherent with treatment prescribed for chronic disease, leading to decreased treatment effectiveness, decreased patient quality of life, and increased healthcare costs.
[1] As clinical research develops new therapies for patients with chronic disease it is important to identify and optimise medication taking behaviours. [3] [4] Treatment non-adherence in respiratory disease is particularly common. For patients with asthma, reported non-adherence rates range from 30-70% [5] and are thought to contribute significantly to the prevalence of severe refractory disease. [6] Most studies quantifying adherence in asthma have focused on children although adults are of equal concern as non-adherence occurs across all demographic categories. [7] In patients with chronic obstructive pulmonary disease (COPD), complex medication regimens and multiple comorbidities result in adherence rates of approximately 50%. [8] A lack of perceived benefit led to 30% of patients with COPD intentionally discontinuing their therapy in one analysis. [9] For both conditions, rates of non- Respiratory disease presents a unique challenge for patient adherence/persistence.
In addition to the common barriers that all patients with chronic disease face, a number of device-related factors complicate the situation, including dislike of inhaled formulations, improper inhaler technique, and need for additional equipment such as spacers.
[10] Of additional importance is how patients perceive their disease in terms of severity and awareness, [11] which for respiratory disease -with a variable symptom time course in asthma, and misunderstanding of disease symptoms as 'normal' in COPD -is an important contributor.
Almost all available respiratory medications are utilised in the treatment of both asthma and COPD. Accordingly, some studies have analysed adherence jointly without regard to diagnosis, [12] [13] despite the different pathology, symptoms and management of each condition. To our knowledge, no single analysis has compared the differences in respiratory medication utilisation between patients with asthma or COPD, and accordingly, the aim of this study was to describe and compare adherence and persistence with inhaled therapies for patients with physiciandiagnosed asthma and COPD in the United Kingdom (UK).
METHODS:

Patients
The present study is a retrospective database cohort analysis of prescribing data from National Health Services (NHS) Forth Valley in Scotland. Data were provided 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 achieved an adequate medication supply, defined as an MPR between 80 and 120%, [17] was also determined; MPRs less than 80% or over 120% were defined as prescribed during each MPR was also quantified. This was achieved by summing the number and size of SABA inhalers to determine the number of total SABA doses prescribed, and then dividing by the number of days over which the maintenance inhaler was prescribed (the denominator of the MPR calculation).
Persistence
Medication persistence was evaluated using a refill-sequence model and defined as the difference in time between the first prescribing of a medication during the study period and either the last prescribing, or an non-permissible gap in therapy (whichever occurred first). [18] [19] A patient was considered to have an unacceptable gap if they failed to receive a prescription within 30 days after their previous medication supply was due to run out. Patients were also classified by whether they were on new or established therapy during the study period; patients were considered to be on 'new' therapy if they had no history of being prescribed an agent in the specified therapeutic class in the six months prior to the start of the study period. At least one prescription for a maintenance medication during the first year of the two-year study period was required to enable accurate calculation of a one-year persistence rate. Median time to discontinuation (TTD) for each patient by therapeutic class was calculated using a Kaplan-Meier survival analysis, with a time censor utilised at one year post-medication initiation.
Statistical analysis
Two binary logistic regression models were utilised to separately assess predictors of adherence and persistence. For adherence, the outcome of interest was Table 2) .
Adequate supply was highest for LAMA inhalers in patients with COPD at 52.2%; patients with COPD had higher incidence of adequate supply and lower incidence of undersupply for all three therapeutic classes available for comparison. Undersupply accounted for approximately one-third to one-half of all episodes, with all therapies for patients with asthma having an undersupply rate of greater than 50%. Oversupply of medication was particularly common for prescribing of ICS in both diseases, at 27.0% for asthma and 34.8% for COPD. In the logistic regression for adherence, both male sex and increasing age were associated with higher odds of achieving an MPR of at least 80% ( Table 3) . Both a diagnosis of COPD and treatment with LAMA were associated with higher odds, although these effects were softened in the multivariate analysis with inclusion of other variables. The number of doses/day of SABA prescribed during the study period increased alongside MPR, with each additional dose/day correlating to an 11% increase in the odds of achieving an adequate MPR; receiving a prescription for OCS was also associated with an increased odds of an adequate MPR, although this effect failed to meet significance for inclusion in the multivariate model.
Medication persistence
For asthma, the overall median TTD was 90 days (IQR: 50-184 days) and for COPD, the overall median TTD was 115 days (IQR: 58-258, comparison p<0.001); the percentage of patients persisting at one year was 11% and 16% for asthma and COPD, respectively (Figure 1) . Persistence by therapeutic class was greater for patients with COPD than asthma for both LABA (96 vs. 61 days, p=0.008) and combination inhalers (116 vs. 85 days, p<0.001), but similar for ICS (101 vs. 100 days). The highest persistence overall was seen for LAMA inhalers in COPD, with a median TTD of 123 days and 18% of patients persisting after one year.
In the logistic regression for persistence, male sex and age were associated with higher odds of persisting past 100 days of therapy ( Table 4) . Therapy with a LAMA or ICS produced the similarly highest odds among therapeutic classes, but diagnosis 
DISCUSSION:
The current analysis demonstrates a relatively low rate of adherence/persistence for inhaled therapies for the treatment of respiratory disease, and reveals that among use of the same medications, patients with asthma and COPD display different medication use behaviour.
Less than one-quarter of patients with asthma and less than one-half of patients with COPD were classified as having an adequate medication supply. Other studies using administrative dispensing databases have demonstrated similar rates to those found in this prescribing analysis. [12] [13] [15] [16] [20] [21] However, to the best of our knowledge, no single analysis has demonstrated enhanced adherence among patients with COPD for the same inhaled therapies within an adjusted analysis.
There is evidence that patients with COPD display more adherent behaviours as they age, [22] and similarly our analysis found that age over 40 years is an independent contributor to having an adequate medication supply. However, older patients also face unique barriers that complicate medication adherence and may not be captured with prescribing data, including cognitive decline, lack of dexterity and polypharmacy. [23] Patients with COPD may also experience more consistent and severe disease symptomology, and may be inclined to be more adherent than patients with asthma. Although the inclusion of patients prescribed more than should correspond with poor adherence to maintenance therapy; accordingly, it has been suggested previously that symptomatic patients may have a weaker sense of control and ownership of their illness, resulting in lower motivation and overall medication adherence. [29] However, the direction of causation in the relationship between reliever and maintenance therapy is unclear, as patients who are symptomatic as defined by increased use of reliever therapy may be inclined to develop better adherence to their maintenance therapy.
[1] The perceived necessity of a medication by the patient has also been shown to correlate with adherence [29] and the relative severity of the disease consequences [11, 30] may further complicate the situation. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 There are several limitations with the current study. All database studies estimate adherence/persistence as it is not always feasible to obtain serum drug concentrations or individually assess patients in large numbers. Access to medication is used as a proxy for adherence in this study and thus we are unable to discern whether the patient actually takes the medication or if he/she uses an inhaler device correctly; therefore, by definition the results are ceiling estimates.
Furthermore, the current study used prescribing data obtained from the GP.
Prescriptions are generally written for an initial supply, and a patient only continues therapy by obtaining a new prescription, either by visiting the GP themselves, or more commonly through a 'managed repeat' service where the pharmacist communicates with the GP for further supply. While the first prescription is initiated by the GP, there is a great degree of patient-initiated action required for follow-up supply, which may influence the large-drop off seen early in therapy. Similarly, hospitalisations, particularly for patients with COPD may lead to changes or disruptions in therapy that effect the calculations. Lastly, the regression models provide an indication of the variables when considered together, but indicate (via the c-statistic) that other variables that were unable to be accounted for within this analysis likely have an effect on the outcome; however, this modest fit is a common finding among adherence studies.
[34] In particular, in a prescribing database, we were unable to correlate the results of the regression with clinical outcomes, such as hospitalisations and overall disease control. However, we attempted to include a proxy for symptoms by quantifying SABA and OCS utilisation among patients.
In conclusion, adherence and persistence with respiratory therapies in this UK cohort was relatively low. There is indication that patients with COPD may display more 
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